DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA

DIAGNOS Inc. has announced progress in the regulatory and commercialization efforts for its AI-powered CARA system, designed to detect various eye-related diseases. The company has been actively advancing its regulatory submissions, including its Medical Device License application to Health Canada, submitted in September 2024. DIAGNOS maintains consistent communication with Health Canada, responding promptly to all inquiries and regulatory requests, reflecting its commitment to fulfilling regulatory requirements and securing approvals essential for market entry. In parallel, DIAGNOS has renewed its FDA Medical Device Establishment Registration in the United States, which supports ongoing and planned commercialization activities in this critical market.

The CARA system leverages advanced AI technology to enable early identification of ophthalmic conditions, underlining DIAGNOS’s strategy to innovate within the medical diagnostic field. The company views CARA as a cornerstone of its growth and expansion plans, especially in key international markets including the U.S. and Canada. By obtaining regulatory clearances, DIAGNOS aims to facilitate broader adoption of CARA by healthcare providers, improving access to non-invasive, reliable early diagnostic tools for eye diseases. This supports a health technology trend where AI plays an increasingly central role in enhancing clinical decision-making while potentially reducing healthcare costs.

Overall, DIAGNOS’s updates signal progress toward commercial deployment of its AI diagnostic technology, positioning it to capitalize on growing demand for AI-driven medical devices within the ophthalmology sector.